Vall d'Hebron Talks by VHIR 'The KDM6A/B inhibition affects viability of SMARCB1 deficient tumors through the disruption of autophagy and angiogenesis in pediatric cancer'

Speaker: Octavio Alfredo Romero Ferraro, principal investigator cancer epigenetics and Biology Program - Josep Carreras Research Institute (IJC) 

In Pediatric cancer, the traditional cytotoxic therapeutic approaches are always a compromise between treatment efficacy and the risk of developing severe secondary 
effects, including new tumours during the adulthood. Our previous study demonstrates that SMARCA4 is necessary to regulate the demethylase activity of 
H3K27me3 in cancer, we discover that the inhibition of KDM6A/B is lethal specifically in SMARCA4 deficient tumors. This discovery implicates a new synthetic lethality, in which inactivating mutations in SWI/SNF members could sensitize cancer cells to specific epigenetic inhibitors affecting pediatric tumours.

Host: Miguel Segura Ginard, main researcher Childhood Cancer and Blood Disorders (VHIR)